Theorem Clinical Research

Genentech

Broad Institute, Calico collaborate on aging

Friday, March 20, 2015 01:56 PM

The Broad Institute of MIT and Harvard has entered into a partnership with Calico around the biology and genetics of aging and early-stage drug discovery. The partnership will support several efforts at the Broad Institute to advance the understanding of age-related diseases and to propel the translation of these findings into new therapeutics.

More... »

Quest Diagnostics

23andMe to create therapeutics group, names Richard Scheller CSO

Thursday, March 12, 2015 01:03 PM

23andMe, a personal genetics company based in Mountain View, Calif., has created a new therapeutics group and has named Richard Scheller, Ph.D., to lead it as chief science officer and head of therapeutics. Scheller retired in December 2014 from a 14-year career at Genentech, where he was executive vice president of research and early development.

More... »


Dr. Anita J. Chawla joins CytRx board of directors

Thursday, March 12, 2015 12:46 PM

CytRx, a biopharmaceutical R&D company specializing in oncology, has appointed Anita J. Chawla, Ph.D., to its board of directors. Chawla brings over 25 years of experience as an economist in the health care industry to CytRx, with a proven track record helping pharmaceutical, biotechnology, medical device and diagnostic companies achieve their product development and commercialization objectives.

More... »

Turing Pharmaceuticals launched

Wednesday, February 25, 2015 11:32 AM

Turing Pharmaceuticals officially has launched. New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there currently are limited or no treatment options.

More... »

FDA grants Genentech’s cobimetinib Priority Review for melanoma

Thursday, February 19, 2015 01:00 PM

The FDA has accepted and granted Priority Review for Genentech’s, a member of the Roche Group, NDA for cobimetinib in combination with Zelboraf (vemurafenib) for the treatment of people with BRAF V600 mutation-positive advanced melanoma. The FDA will make a decision on approval by Aug. 11.

More... »

Adimab, Sanofi collaborate on bispecific antibodies

Monday, February 9, 2015 12:20 PM

Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

More... »

23andMe, Genentech partner to analyze genomic data for Parkinson’s

Thursday, January 8, 2015 01:00 PM

23andMe, a privately held personal genomics and biotechnology company based in Mountain View, Calif., has inked an agreement with Genentech, a member of the Roche Group, to generate whole genome sequencing data for approximately 3,000 people in 23andMe’s Parkinson’s disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson’s disease.

More... »

Global oncologists share insights into cancer immunology

Monday, November 24, 2014 08:00 AM

Cancer immunotherapy has become one of the hottest fields of clinical research in decades.

More... »

Cancer Innovation Coalition calls for reinvigorated U.S. cancer innovation

Friday, October 31, 2014 02:10 PM

The Cancer Innovation Coalition (CIC) has gone to Capitol Hill to call for early legislative and regulatory action in 2015 that will reinvigorate cancer innovation in the U.S.

More... »

Cancer Innovation forum calls for improving cancer research ecosystem

Monday, October 27, 2014 12:58 PM

Accelerating the delivery of promising new cancer treatments depends on one critical requirement—ensuring patients are actively involved in the cancer research and drug development process from beginning to end.

More... »


CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs